Kangstem Biotech Past Earnings Performance
Past criteria checks 0/6
Kangstem Biotech's earnings have been declining at an average annual rate of -3.3%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 17.7% per year.
Key information
-3.3%
Earnings growth rate
12.9%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 17.7% |
| Return on equity | -46.3% |
| Net Margin | -172.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Kangstem Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 12,704 | -21,949 | 10,272 | 14,030 |
| 30 Sep 23 | 14,798 | -21,858 | 10,942 | 14,186 |
| 30 Jun 23 | 15,101 | -21,794 | 10,954 | 14,259 |
| 31 Mar 23 | 16,254 | -20,670 | 10,896 | 14,134 |
| 31 Dec 22 | 16,301 | -20,236 | 11,076 | 14,220 |
| 30 Sep 22 | 15,423 | -22,709 | 12,824 | 15,189 |
| 30 Jun 22 | 15,948 | -21,950 | 12,296 | 15,025 |
| 31 Mar 22 | 14,614 | -21,338 | 11,861 | 15,049 |
| 31 Dec 21 | 12,405 | -21,348 | 10,636 | 14,653 |
| 30 Sep 21 | 10,712 | -18,841 | 7,671 | 13,206 |
| 30 Jun 21 | 8,577 | -17,479 | 7,273 | 12,512 |
| 31 Mar 21 | 9,101 | -16,172 | 7,094 | 12,646 |
| 31 Dec 20 | 9,138 | -18,471 | 6,799 | 12,639 |
| 30 Sep 20 | 8,608 | -23,751 | 8,142 | 13,421 |
| 30 Jun 20 | 8,026 | -24,886 | 8,462 | 13,661 |
| 31 Mar 20 | 6,475 | -27,651 | 9,587 | 13,066 |
| 31 Dec 19 | 6,005 | -24,635 | 9,994 | 12,415 |
| 30 Sep 19 | 5,997 | -18,973 | 8,830 | 10,639 |
| 30 Jun 19 | 8,572 | -17,123 | 8,524 | 9,035 |
| 31 Mar 19 | 8,874 | -15,332 | 6,891 | 7,436 |
| 31 Dec 18 | 9,165 | -13,648 | 6,406 | 6,181 |
| 30 Sep 18 | 8,411 | -13,773 | 4,451 | 5,466 |
| 30 Jun 18 | 7,276 | -15,699 | 5,813 | 6,200 |
| 31 Mar 18 | 9,156 | -15,141 | 7,994 | 6,475 |
| 31 Dec 17 | 9,133 | -15,423 | 8,060 | 6,715 |
| 30 Sep 17 | 7,587 | -12,323 | 9,241 | 6,663 |
| 30 Jun 17 | 5,122 | -10,089 | 7,140 | 5,871 |
| 31 Dec 16 | 843 | -8,300 | 4,246 | 5,529 |
Quality Earnings: A217730 is currently unprofitable.
Growing Profit Margin: A217730 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A217730 is unprofitable, and losses have increased over the past 5 years at a rate of 3.3% per year.
Accelerating Growth: Unable to compare A217730's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A217730 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A217730 has a negative Return on Equity (-46.33%), as it is currently unprofitable.